Orteronel

• Description:

  Orteronel (TAK-700) is a highly selective inhibitor of human 17,20-lyase (CYP17) with IC50 of 38 nM, and exhibits >1000-fold selectivity over other CYPs such as 11-hydroxylase and CYP3A4[1][2].

• Product Name Alternative:

  TAK-700

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H317, H318, H334, H335, H341, H361, H370, H413

• Target:

  Cytochrome P450

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Orteronel.html

• Concentration:

  10mM

• Purity:

  99.90

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC=C2C=C([C@@]3(O)CCN4C=NC=C43)C=CC2=C1)NC

• Molecular Formula:

  C18H17N3O2

• Molecular Weight:

  307.35

• Precautions:

  H315, H317, H318, H334, H335, H341, H361, H370, H413

• References & Citations:

  [1]Yamaoka M, et al. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol. 2012 Apr;129 (3-5) :115-28.|[2]Kaku, Tomohiro., et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. From Bioorganic & Medicinal Chemistry (2011), 19 (21), 6

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 3

• Isoform:

  CYP17

• CAS Number:

  [566939-85-3]